Skip to content
cccskills
FreePublished on GitHub

enda-avoid-dexamethasone-pai

Recommends against dexamethasone for glucocorticoid replacement in primary adrenal insufficiency (PAI) due to risk of Cushingoid side effects from difficult dose titration. Use when selecting a glucocorticoid for PAI management to avoid iatrogenic Cushing syndrome.

The English summary is being prepared. Showing the original description.

See how to install

Files included (1)

  • SKILL.md1.9 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Avoid Dexamethasone for PAI Treatment Due to Cushingoid Side Effects

STEP 1 — Gather Information

Confirm diagnosis of primary adrenal insufficiency (PAI) and assess need for glucocorticoid replacement therapy.

STEP 2 — Rule In / Rule Out

Is dexamethasone being considered for glucocorticoid replacement in PAI? If yes, proceed to avoid; if no, continue with standard glucocorticoid selection.

STEP 3 — Classify or Stratify

Classify glucocorticoid options into preferred (hydrocortisone, cortisone acetate, prednisolone) and non-preferred (dexamethasone) for PAI based on Cushingoid risk and titration difficulty.

STEP 4 — Decide

Select a preferred glucocorticoid (hydrocortisone 15–25 mg/day or cortisone acetate 20–35 mg/day in divided doses) and avoid dexamethasone for PAI treatment.

Clinical Guardrails / Mimics / Pitfalls

Do not use dexamethasone for PAI due to its long half-life and lack of mineralocorticoid activity, which complicates dose titration and increases Cushingoid risk; avoid in pediatric patients; monitor for weight gain, hyperglycemia, hypertension if inadvertently used; do not rely on dexamethasone for emergency dosing.

Concrete Clinical Example

A 50-year-old woman with confirmed PAI is being evaluated for glucocorticoid replacement; the clinician considers dexamethasone for once-daily convenience but chooses hydrocortisone 20 mg daily in two divided doses after reviewing guideline 3.4 to prevent Cushingoid complications.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill